About the P. vivax information hub
Video on life-changing treatment to cure relapsing P. vivax malaria.
Vivax Working Group Annual meeting
15 -17th October Nepal
The Malaria in Pregnancy (MiP) Library now available on WWARN.
Primaquine prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria.
Tafenoquine for Plasmodium vivax malaria is heralded among the five new developments in the field of tropical medicine in 2018.
This technical brief developed by the World Health Organisation reviews the biological characteristics, geographical distribution and worldwide burden of P. vivax malaria.
This technical brief features discussions on translating guidelines into policy and strategy in programmes for the control and elimination of Plasmodium vivax malaria.
This 2-day invitation-only event is focused on the development of strategies for implementation of new tools and approaches to radical cure for malaria.
Traditionally, patient travel history has been used to identify imported cases, but the long-latency liver stages confound this approach in Plasmodium vivax. Molecular tools to identify and map imported cases offer a more robust approach.
The research investigated the prevalence and characteristics of splenic complications in patients with vivax malaria from 2005 to 2017 in a university hospital.
The objective of this study was to collect data on chloroquine resistance in French Guiana by associating a retrospective evaluation of the therapeutic efficacy and an analysis of recurrent parasitemia from any patients.
Our results indicate that PvRBP2b warrants further preclinical development as a blood-stage vaccine candidate against P. vivax. Total IgG responses to PvRBPs were also shown to be promising immunological markers of exposure to P. vivax infection.